The estimated Net Worth of Pharmaceuticals Internation... is at least $200 Million dollars as of 17 April 2017. Pharmaceuticals Internation owns over 4,432 units of Myovant Sciences Ltd stock worth over $200,208,463 and over the last 8 years Pharmaceuticals sold MYOV stock worth over $0.
Pharmaceuticals has made over 4 trades of the Myovant Sciences Ltd stock since 2016, according to the Form 4 filled with the SEC. Most recently Pharmaceuticals exercised 4,432 units of MYOV stock worth $119,575 on 17 April 2017.
The largest trade Pharmaceuticals's ever made was exercising 1,977,269 units of Myovant Sciences Ltd stock on 1 November 2016 worth over $53,346,718. On average, Pharmaceuticals trades about 507,376 units every 42 days since 2016. As of 17 April 2017 Pharmaceuticals still owns at least 7,420,625 units of Myovant Sciences Ltd stock.
You can see the complete history of Pharmaceuticals Internation stock trades at the bottom of the page.
Pharmaceuticals's mailing address filed with the SEC is Thurgauerstrasse 130, 8152 Opfikon, Switzerland.
Over the last 8 years, insiders at Myovant Sciences Ltd have traded over $5,780,890 worth of Myovant Sciences Ltd stock and bought 96,585,963 units worth $2,001,605,371 . The most active insiders traders include Sciences Ltd. Roivant, Global Investors Lp Viking ..., and Andrew Lo. On average, Myovant Sciences Ltd executives and independent directors trade stock every 15 days with the average trade being worth of $25,106,967. The most recent stock trade was executed by Chemical Co., Ltd.Sumitomo ... on 10 March 2023, trading 51,599,200 units of MYOV stock currently worth $1,393,178,400.
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Myovant Sciences has one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Its lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. Myovant Sciences is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is its majority shareholder.
Myovant Sciences Ltd executives and other stock owners filed with the SEC include: